Nevro to Present at the Canaccord Genuity 42nd Annual Growth Conference
Nevro Corp. (NYSE: NVRO), a medical device company based in Redwood City, California, will have CFO Rod MacLeod present at the Canaccord Genuity 42nd Annual Growth Conference. The event is scheduled for August 10, 2022, at 2:30 pm Eastern Time, in Boston, MA. Investors can access a live webcast and subsequent recording on Nevro's website. Nevro specializes in innovative solutions for chronic pain, including the proprietary 10 kHz Therapy, which has benefited over 80,000 patients worldwide. For more details, visit www.nevro.com.
- None.
- None.
Wednesday, August 10, 2022 at 2:30 pm Eastern Time
REDWOOD CITY, Calif., July 21, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Rod MacLeod, Nevro's Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 2:30 pm Eastern Time at the InterContinental Boston Hotel in Boston, MA.
A webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 80,000 patients globally.
Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic trunk and limb pain and painful diabetic neuropathy. Senza®, Senza II®, and Senza Omnia™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy. Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.
Senza, Senza II, Senza Omnia, HFX, HXF Coach, HFX Cloud, HFX Connect, Nevro and the Nevro logo are trademarks of Nevro Corp.
To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.
Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Chief Corp Communications and Investor Relations Officer
650-433-3247 | julie.dewey@nevro.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-to-present-at-the-canaccord-genuity-42nd-annual-growth-conference-301590779.html
SOURCE Nevro Corp.
FAQ
When is Nevro's presentation at the Canaccord Genuity 42nd Annual Growth Conference?
Who will present for Nevro at the conference?
Where is the Canaccord Genuity 42nd Annual Growth Conference located?
How can investors access information from Nevro's conference presentation?
What is Nevro's focus in the medical device industry?
How many patients have benefited from Nevro's 10 kHz Therapy?
